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Abstract
Objective
Carnitine plays a significant role in fatty acid transportation in 
mitochondria and has been shown to have a prophylactic effect on 
adult migraine. The aim of this randomized controlled trial was to 
compare and evaluate the effects of L-carnitine supplementation 
versus propranolol in the prevention of pediatric migraine. 
Materials & Methods
A total of 60 pediatric patients with episodic migraine were randomly 
allocated to 2 independent groups to receive either 50 mg/kg/day 
L-carnitine or 1 mg/kg/day propranolol as a prophylactic drug. 
Frequency, severity, and duration of migraine attacks and headache 
disability based on the Pediatric Migraine Disability Assessment 
Score (PedMIDAS) were studied at the baseline and after 2, 4, and 
12 weeks.
Results
A total of 56 patients were evaluated in the study: 23 girls (41%) 
and 33 boys (59%) with a mean age of 9.7 ± 2.1 years. Frequency 
of migraine headaches per month reduced from 11.4 ± 7.1 to 5.34 ± 
2.4 in the L-carnitine group and from 10.7 ± 6.2 to 4.96 ± 3.9 in the 
propranolol group by the end of the study. Headache severity score 
was also reduced from 19.38 ± 14 to 2.88 ± 7.4 and from 12.92 ± 13 to 
0.82 ± 1.3 in the L-carnitine and propranolol groups, respectively. We 
found a significant decrease in frequency, severity, and duration of 
headache attacks in both groups (P < 0.01). No significant difference 
was observed between the efficacies of the 2 drugs.
Conclusion
This study concluded that L-carnitine supplementation can play a 
prophylactic role in the management of pediatric migraine.
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Introduction
Migraine is the most frequent type of headache 
in both adults and children and accounts for 
75% of headaches in young children referred for 
neurological consultation (1, 2). Pulsating head 
pain accompanied by increased sensitivity to 
environmental stimuli, such as light (photophobia) 
or sound (phonophobia), and/or gastrointestinal 
symptoms are the main diagnostic features of a 
migraine attack (3).
Prevalence of migraine is reported to be around 
1%–3% in 3–7 years-old and 4%–11% in 7–11 
years old, which increases to 8%–23% by the age 
of 15 years (4), and while it may not be a life-
threatening illness in the majority of patients, it can 
severely interfere with the daily life of a growing 
child, including academic performance, quality of 
life, and leisure activities (5, 6). 
A full understanding of the pathophysiology 
of migraine is still not available. Besides the 
common vascular and neuronal theories (7-9), 
impaired oxygen metabolism due to mitochondrial 
disorders has been hypothesized since the 1980s 
(10-13). Since then, numerous studies have tested 
this hypothesis and various types of evidence 
(including biochemical, morphological, genetic, 
and therapeutic) are reported, which further 
supports the association between mitochondrial 
disorders and migraine-type headaches (14). 
The treatment strategy for migraine is divided into 
acute and preventive therapy (15). Beta-adrenergic 
receptor antagonists (beta-blockers) were the first 
class of migraine prophylactic medications, which 
still have a firm place in preventive therapy and 
have shown to be very effective in reducing the 
frequency and severity of migraine attacks when 
used at an optimum dose (16). Beta-blockers 
exert their effect mainly centrally by modifying 
neuronal excitability. Also, there is a report that 
their preventive action is mediated through beta-1 
adrenoceptor inhibition in nociceptive neurons in 
the thalamus. Antagonist effects of beta-blockers 
on 5-hydroxytryptamine (serotonin or 5-HT) 
receptors and inhibition of nitrous oxide production 
are other suggested mechanisms (17). 
Carnitine is necessary in the mitochondrial oxidation 
of fatty acids and stimulates lipid-mediated 
energy production in the central nervous system. 
Any faults in this mechanism could lead to toxin 
accumulation, which then potentiates nociceptive 
triggers (14). L-carnitine, the biologically active 
form of carnitine, facilitates β-oxidation by 
helping the transport of activated long-chain fatty 
acids from the cytosol to the mitochondrial matrix. 
Due to its important role in the central metabolism 
of the human body, it has been used as a migraine 
prophylactic agent. Besides, oxidative stress along 
with decreased antioxidant defenses are other 
associated factors in the pathogenesis of migraine 
headache (18). Carnitine might play a prophylactic 
role due to its potent antioxidant activity, which 
protects the cells against oxidative injury (19). 
Various forms of carnitine have been shown to be 
effective as a potent prophylactic nutraceutical agent 
for migraine in the adult population with minimal 
side effects (20, 21); therefore, we evaluated the 
efficacy of L-carnitine supplementation versus 




Guidelines of the International Headache Society 
were considered for the design and conduct of 
this randomized controlled trial (22). Subjects 
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were chosen from those who were referred to 
the pediatric neurology clinics of Imam Hossein 
Children’s Hospital and Al-Zahra Hospital, 
between September 2018 and February 2019, 
in Isfahan, Iran. All referred children between 
5 and 15 years of age who met the International 
Classification of Headache Disorder III (ICHD-
III) (23) criteria for episodic migraine with or 
without any history of aura were enrolled for this 
randomized clinical trial. All participants were 
newly diagnosed with at least 1 migraine attack 
per week. None was receiving any prophylactic 
drugs at the start of this study. Two expert pediatric 
neurologists examined all the participants in the 
first visit to confirm the diagnosis and inclusion 
criteria, from which 60 were subsequently enrolled 
for this trial. Children suffering from metabolic 
acidosis, kidney dysfunction, any serious systemic 
diseases, secondary headaches, or headaches other 
than migraine were not included. 
Subjects were excluded from this clinical trial if 
they did not adhere to the study protocol, missed 
their follow-up visits, experienced any severe 
adverse drug reactions, experienced continuous 
headaches, or if the diagnosis was changed during 
the course of the study. 
The protocol of the study was clearly explained 
to all parents or the legal guardian of the child 
and a written consent form was signed before 
participation. 
Study design
All parents were informed about the clinical trial 
and that their child would either receive a drug or 
a nutraceutical supplement. If they consented to 
join, their child was assigned to group 1 or group 
2 using a randomized number list created before 
the start of the study. The first group received 
L-carnitine (50 mg/kg), which was divided into 
2 doses per day, and the second group received 1 
dose of propranolol (1 mg/kg) daily. Participants 
did not take any other migraine prophylactic 
drugs during the course of this study. An analgesic 
or nonsteroidal anti-inflammatory drug was 
prescribed in the case of an acute attack and the 
patients were advised to refer to the clinic if their 
headache continued after 2 days.
Data gathering
A data form containing demographic data and 
questions regarding the headache type, severity, 
frequency, duration, accompanying symptoms, 
and headache disability was filled in the first visit. 
These data were collected by a neurologist, who 
filled in the questionnaires during a face-to-face 
interview with the parents of the child. 
The Pediatric Migraine Disability Assessment 
Score (PedMIDAS) questionnaire was used for 
assessing headache disability and the impact of 
migraine headaches in children and to monitor 
their response to treatment (24). Follow-up 
appointments were arranged after 2 weeks, 1 
month, and 3 months of the first visit.
Side effects
At each follow-up visit, the participating children 
and their parents were asked about any adverse 
drug events. Four patients in group 1 (receiving 
L-carnitine supplementation) were excluded from 
the study due to gastric cramps and stomachache 
(3 cases) and vomiting (1 case). 
Statistical analysis
The Kolmogorov–Smirnov test was used to assess 
the normality of the collected data. The Mann–
Whitney, Friedman, and chi-square tests were 
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implemented to explore the differences between the 
groups. Statistical analysis was done using SPSS 
for Windows version 20 (SPSS Inc., Chicago, IL, 
USA) and P-value below 0.05 was considered as 
significant. 
Results
A total number of 60 participants were enrolled, 
out of which 56 patients completed the study. A 
total of 31 patients received L-carnitine (group 1) 
and the remaining 29 patients received propranolol 
(group 2). Four patients of group 1 were excluded 
due to gastric complaints. The average age of the 
patients in group 1 and 2 was 9.6 ± 1.9 and 9.8 
± 2.4 years, respectively. No significant difference 
was observed between the groups in terms of age 
and gender of patients (P < 0.01). Table 1 shows 
the demographic specifications of the participants.
Our study indicated that both L-carnitine and 
propranolol significantly lower the number of 
headache attacks. Mean number of migraine attacks 
per month was 11.4 in the L-carnitine group and 
10.7 in the propranolol group, which dropped to 
5.34 and 4.96, respectively, by the end of this study 
(Table 2).
Severity score of attacks (based on the PedMIDAS 
questionnaire) decreased in both groups, from 
19.38 to 2.8 in the L-carnitine group and from 
12.92 to 0.82 in the propranolol group (mean ± 
SD). This reduction in severity of headache attacks 
was statistically significant in both groups (Table 
3).
At the beginning of the study, about 15% of 
participants in both groups suffered migraine 
attacks, which lasted for more than 6 hours. 
This number was reduced to zero after 1 month 
of prophylactic therapy. In general, both drugs 
significantly lowered the duration of headache 
attacks (Table 4).
This research project demonstrates that both 
L-carnitine and propranolol significantly reduce 
the average headache frequency, duration, and 
severity in pediatric patients. However, no 
significant difference was observed between the 
efficacies of the two drugs during the course of the 
study.
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Table 1. Comparing age distribution of participants between the two groups.
Age groups (year) L-carnitine group Propranolol group Total
5-8 4 (15%) 5 (17%) 9 (16%)
8-11 12 (44%) 11 (38%) 23(41%)
11-15 11 (41%) 13 (45%) 24(43%)
Total 27 29 56
Data is presented as N(%).
Table 2. Comparing migraine headache frequency per month between the two groups at baseline and each visit.
Group Baseline After 2 weeks After 4 weeks After 12 weeks P-value
L-carnitine 11.4 ± 7.1 7.84 ± 4.1 6.42 ± 3.5 5.34 ± 2.4 < .01
Propranolol 10.7 ± 6.2 6.71 ± 3.5 7.35 ± 4.4 4.96 ± 3.9 < .01
Data is presented as mean ± standard deviation. The difference in headache frequency between the two 
groups at each visit was not statistically significant (p > 0.1).
Table 3. Comparing migraine headache severity score based on PedMIDAS questionnaire between the two groups at baseline and 
each visit.
Group Baseline After 2 weeks After 4 weeks After 12 weeks P-value
L-carnitine 19.38 ±14 3.23 ± 3.7 1.8 ± 3 2.88 ± 7.4 < .001
Propranolol 12.92 ±13 2.32 ± 3.2 1.5 ± 2.2 0.82 ± 1.3 < .001
P-value 0.055 0.254 0.919 0.767
Data is presented as mean ± standard deviation.
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Discussion
It is reported that up to 75% of children experience 
headaches by the age of 15 years, from which 
migraine headache is the most frequent type 
and occurs in up to 28% of teenagers (25). This 
debilitating ailment has a significant effect on the 
social and academic life of a child, which will 
be even more aggravated if there are any other 
psychological co-morbidities like depression or 
anxiety. It causes absenteeism in school, exclusion 
from social interactions, and also exerts a great 
economic burden on the parents as a result of 
increased healthcare and admission costs.
Different pharmacologic regimens are advised 
for migraine prophylaxis, but the safety of the 
prescribed drugs in pediatric patients is still not 
clear (3), and there are even some reports that 
question the risk–benefit ratio of such preventive 
therapies (6). In recent years, the focus has shifted 
toward nutraceutical agents that have a role to 
play in the cellular metabolic chain. The efficacy 
of such agents has been studied in adult patients 
(20, 21), but this effect needs to be assessed and 
confirmed in pediatric patients because childhood 
and adult migraines exhibit slightly different 
behaviors (26). From this list, carnitine is a 
potential complementary approach and has shown 
evidence of efficacy (19, 27). 
Tarighat et al evaluated the effects of magnesium, 
L-carnitine, and concurrent magnesium–
L-carnitine supplementation in migraine 
prophylaxis. L-carnitine supplementation was 
shown to significantly decrease migraine duration, 
frequency, and severity (20). There is also a report 
that patients with carnitine palmitoyltransferase II 
deficiency suffer migraine-type headache, which 
is alleviated by carnitine supplementation (21). 
Despite the above-mentioned studies, in a triple-
blind crossover study, Hagen et al did not observe 
any significant differences in headache outcomes 
between acetyl-carnitine and placebo (28).
On the other hand, propranolol is a nonselective 
beta-blocker that is highly lipid soluble and can 
easily reach the central nervous system to exert its 
effect. Propranolol was the first beta-blocker that 
was used for prophylactic migraine therapy, and 
its effect compared to placebo has been confirmed 
by several trials (29, 30). Favorable efficacy of 
propranolol is tested in pediatric studies; Eidlitz-
Markus et al measured the effects of low-dose 
propranolol versus amitriptyline for treating severe 
pediatric migraine. This study showed that the 
response rate was higher than previously reported 
results for placebo, and both drugs were effective on 
reducing migraine headache frequency. However, 
propranolol should be preferred due to its lower 
risk of side effects. Response to propranolol was 
also significantly better in those who experience 
migraine headaches without aura compared to 
migraine with aura (31). In another randomized 
clinical trial by Togha et al, the prophylactic 
efficacy and safety of cinnarizine was compared 
to propranolol. Cinnarizine reduced the baseline 
headache frequency by more than 50% in 74.6% 
of patients,  and more than 50% reduction of the 
baseline headache frequency was seen in 72.5% of 
patients in the propranolol group. No significant 
difference was seen between the 2 groups (32). or 
sodium valproate (33) in reducing the frequency, 
severity, and duration of migraine attacks.
A majority of patients who are placed on a migraine 
preventive treatment will require long-term 
therapy. Therefore, it is very important to select 
the safest available medicine with the least critical 
potential adverse side effects. Beta-blockers are 
associated with impaired glucose tolerance and 
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an increased risk of new-onset diabetes (34-35). 
Hypotension, depression, and dizziness are the 
most common reported side effects of propranolol, 
and it should be avoided in children with asthma or 
liver pathology (17-36). This indicates the need for 
new treatment modalities in migraine prophylactic 
approaches.
In this randomized controlled trial, we assessed the 
prophylactic effects of L-carnitine supplementation 
on migraine headache compared to propranolol in 
a sample of pediatric patients. Current findings 
showed a positive prophylactic role for L-carnitine 
in pediatric migraine, which is in agreement with 
the previous reports on adult population (20, 21). 
Frequency, severity, and duration of the migraine 
attacks were reduced in both groups, but the 
difference between the efficacies of the 2 drugs 
was not significant.
A total of 4 out of 31 patients treated with L-carnitine 
manifested side effects (3 cases of gastric cramps 
and stomachache and 1 case of vomiting), who 
were subsequently excluded. No serious or life-
threatening drug adverse effects were reported 
during the course of this study.
The main limitation of this research was that our 
study design was not blinded and we did not have 
a placebo group due to ethics considerations. We 
believed it is ethically wrong to administer placebo 
to children who suffer from recurrent debilitating 
pain. 
In Conclusion
Current study indicated that L-carnitine 
supplementation at 50 mg/kg/day could be used as 
an effective complementary therapy for pediatric 
migraine prophylaxis. It was well tolerated and 
had a significant effect on increasing the quality 
of life of children who suffer from migraine. 
However, patients’ compliance and preferences 
must be considered before prescribing this agent 
and studies with bigger sample size and longer 
follow-up time are recommended.
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